Home
  >  
Section 70
  >  
Chapter 69,536

Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: a Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers

El-Masry, S.M.; El-Khodary, N.M.

Drug Research 70(2-03): 91-96

2020

ISSN/ISBN: 2194-9387
PMID: 31746448
DOI: 10.1055/a-1035-9212
Accession: 069535023
Download citation:  
Text
  |  
BibTeX
  |  
RIS
Nifedipine is one of calcium channel blockers that commonly used clinically to treat hypertension and angina in Egyptian patients. A sustained-release (SR) formulation of nifedipine is available in the Egyptian community and administered twice daily. This study aimed to to compare the pharmacokinetics and safety profiles of a 20 mg SR and IR (immediate release) formulation of nifedipine after single-dose administration in healthy Egyptian subjects. Randomized, crossed open-label two- way clinical trial, in 16 healthy adult volunteers, of 24.75±5.20 years, with BMI 23.26±1.756 were assessed. Blood samples were collected at predefined times for 48 h and analyzed for Nifedipine plasma concentrations using validated reversed phase liquid chromatography method with ultraviolet detection. Pharmacokinetics was determined using non- compartmental model pharmacokinetics and analyzed using one-way ANOVA (P≤0.05). Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively. There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively). SR formulation of nifedipine showed similar pharmacokinetics to the IR Formulation (F%=1.049), but it additionally allows a less frequent administration. Therefore, The nifedipine SR and IR formulations were well tolerated and displayed comparable safety profiles.

Full Text Article emailed within 0-6 h: $19.90




Related References

Zhai, X.-J.; Hu, K.; Chen, F.; Lu, Y.-N. 2013: Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study Current Therapeutic Research 75: 48-52
Shi, S.; Liu, Y.; Wu, J.; Li, Z.; Zhao, Y.; Zhong, D.; Zeng, F. 2010: Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study Clinical Therapeutics 32(11): 1977-1986
Zou, J.-J.; Ji, H.-J.; Wu, D.-W.; Yao, J.; Hu, Q.; Xiao, D.-W.; Wang, G.-J. 2008: Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study Clinical Therapeutics 30(9): 1651-1657
Liu, Y-Mei.; Liu, G-Yi.; Liu, Y.; Li, S-Jun.; Jia, J-Ying.; Zhang, M-Qi.; Lu, C.; Zhang, Y-Mei.; Li, X-Ning.; Yu, C. 2009: Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male volunteers Clinical Therapeutics 31(8): 1787-1795
Zou, J.; Di, B.; Wu, C.Yong.; Hu, Q.; Li, J.Hua.; Zhu, Y.; Fan, H.; Xiao, D.; Wang, G.Ji. 2008: Pharmacokinetic and bioequivalence comparison of a single 100-mg dose of cefteram pivoxil powder suspension and tablet formulations: a randomized-sequence, open-label, two-period crossover study in healthy Chinese adult male volunteers Clinical Therapeutics 30(4): 654-660
Yu, J.; Ma, K.; Qi, J.; Jin, G.; Wang, Y.; Fang, S.; Li, G. 2008: Bioequivalence and comparison of pharmacokinetic properties of 4-mg tablet formulations of rosiglitazone hydrochloride and rosiglitazone maleate: a single-dose, randomized, open-label, two-period crossover study in healthy adult male Chinese volunteers Clinical Therapeutics 30(12): 2272-2279
Lee, D.; Lim, L.A.; Jang, S.B.; Lee, Y.J.; Chung, J.Y.; Choi, J.R.; Kim, K.; Park, J.W.; Yoon, H.; Lee, J.; Park, M.S.; Park, K. 2011: Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study Clinical Therapeutics 33(12): 2038-2053
Alkhalidi, B.A.; Tamimi, J.J.; Salem, I.I.; Ibrahim, H.; Sallam, A.A.I. 2008: Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers Clinical Therapeutics 30(10): 1831-1843
Maanen, R.v.; Bentley, D. 2009: Bioequivalence of zonisamide orally dispersible tablet and immediate-release capsule formulations: results from two open-label, randomized-sequence, single-dose, two-period, two-treatment crossover studies in healthy male volunteers Clinical Therapeutics 31(6): 1244-1255
Homero de Souza Filho, J.é; Bonifácio, F.N.; Bedor, D.C.és.G.; Ramos, V.L.; de Sousa, C.E.M.; Sardón, L.L.F.; Gonçalves, T.M.; Moreira, R.C.D.; Leal, L.B.; de Santana, D.P. 2010: Relative bioavailability of two formulations of venlafaxine extended-release 75-mg capsules in healthy brazilian male volunteers: a single-dose, randomized-sequence, open-label, two-period crossover study in the fasting and fed states Clinical Therapeutics 32(12): 2088-2096
Iqbal, M.; Khuroo, A.; Batolar, L.S.; Tandon, M.; Monif, T.; Sharma, P.L. 2010: Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers Clinical Therapeutics 32(3): 588-596
Liu, Y.; Lu, C.; Chen, Q.; Wang, W.; Liu, G.-Y.; Lu, X.-P.; Zhang, M.-Q.; Yu, C.; Jia, J.-Y. 2013: Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers Drug Research 63(2): 74-78
Liu, Y.; Lu, C.; Chen, Q.; Wang, W.; Liu, G.Y.; Lu, X.P.; Zhang, M.Q.; Yu, C.; Jia, J.Y. 2013: Bioequivalence and Pharmacokinetic Evaluation of Two Tablet Formulations of Carvedilol 25-mg: A Single-Dose, Randomized-Sequence, Open-Label, Two-Way Crossover Study in Healthy Chinese Male Volunteers Drug Research (Stuttgart 2013. Print) 63(2): 74-78
Monif, T.; Rao Thudi, N.; Koundinya Tippabhotla, S.; Khuroo, A.; Marwah, A.; Kumar Shrivastav, V.; Tandon, M.; Raghuvanshi, R.; Biswal, S. 2007: A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers Clinical Therapeutics 29(12): 2677-2684
Monif, T.; Reyar, S.; Tiwari, H.K.; Tippabhotla, S.K.; Khuroo, A.; Thudi, N.R.; Ahmed, S.; Raghuvanshi, R. 2009: A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers Arzneimittel-Forschung 59(2): 104-108
Liu, Y.; Zhang, M.-q.; Jia, J.-y.; Liu, Y.-m.; Liu, G.-y.; Li, S.-j.; Wang, W.; Weng, L.-p.; Yu, C. 2013: Bioequivalence and pharmacokinetic evaluation of two formulations of risperidone 2 mg : an open-label, single-dose, fasting, randomized-sequence, two-way crossover study in healthy male Chinese volunteers Drugs in R&d 13(1): 29-36
Zhang, Q.; Wang, Z.; Wu, J.; Zhou, Z.; Zhou, R.; Hu, W. 2021: Bioequivalence and Pharmacokinetic Evaluation of two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions Drug Design Development and Therapy 15: 3277-3288
Choi, H.-G.; Jeon, J.-Y.; Im, Y.-J.; Kim, Y.; Jang, H.; Kang, S.; Kim, K.H.; Chae, S.-W.; Lee, S.Y.; Kim, M.-G. 2014: Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study International Journal of Clinical Pharmacology and Therapeutics 52(1): 55-63
Liu, M.-Y.; Wang, S.; Yao, W.-F.; Wu, H.-z.; Meng, S.-N.; Wei, M.-J. 2009: Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers Clinical Therapeutics 31(4): 784-792
Lee, S.; Chung, Y.-J.; Kim, B.-H.; Shim, J.-H.; Yoon, S.-H.; Shin, S.-G.; Jang, I.-J.; Yu, K.-S. 2009: Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers Clinical Therapeutics 31(12): 3000-3008